- Home
- NABL vs SLNO Comparison
NABL vs SLNO Comparison
Compare NABL & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NABL
- SLNO
- Stock Information
- Founded
- NABL 2000
- SLNO 1999
- Country
- NABL United States
- SLNO United States
- Employees
- NABL N/A
- SLNO N/A
- Industry
- NABL Computer Software: Prepackaged Software
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- NABL Technology
- SLNO Health Care
- Exchange
- NABL Nasdaq
- SLNO Nasdaq
- Market Cap
- NABL 1.9B
- SLNO 2.2B
- IPO Year
- NABL N/A
- SLNO 2014
- Fundamental
- Price
- NABL $10.02
- SLNO $47.65
- Analyst Decision
- NABL Strong Buy
- SLNO Strong Buy
- Analyst Count
- NABL 2
- SLNO 6
- Target Price
- NABL $15.75
- SLNO $74.83
- AVG Volume (30 Days)
- NABL 492.7K
- SLNO 705.0K
- Earning Date
- NABL 11-07-2024
- SLNO 11-06-2024
- Dividend Yield
- NABL N/A
- SLNO N/A
- EPS Growth
- NABL 72.50
- SLNO N/A
- EPS
- NABL 0.20
- SLNO N/A
- Revenue
- NABL $458,053,000.00
- SLNO N/A
- Revenue This Year
- NABL $11.99
- SLNO N/A
- Revenue Next Year
- NABL $9.74
- SLNO N/A
- P/E Ratio
- NABL $50.49
- SLNO N/A
- Revenue Growth
- NABL 11.93
- SLNO N/A
- 52 Week Low
- NABL $9.98
- SLNO $35.70
- 52 Week High
- NABL $15.49
- SLNO $60.92
- Technical
- Relative Strength Index (RSI)
- NABL 31.02
- SLNO 37.97
- Support Level
- NABL $10.13
- SLNO $45.00
- Resistance Level
- NABL $10.50
- SLNO $48.77
- Average True Range (ATR)
- NABL 0.20
- SLNO 2.20
- MACD
- NABL 0.05
- SLNO -0.42
- Stochastic Oscillator
- NABL 0.00
- SLNO 19.09
About NABL N-able Inc.
N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. it also has a presence in the United Kingdom and all other International regions.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.